Suchergebnisse - "Lindegaard, Hanne"

PubPharm (9)

1

Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : an observational nationwide study applying linkage between DANBIO and national registries

enthalten in: Annals of the rheumatic diseases | 2020

von Glintborg, B. | Georgiadis, S. | Loft, A. | +18

2

Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al

enthalten in: Annals of the rheumatic diseases | 2020

von Glintborg, B. | Loft, A. | Omerovic, E. | +21

CommentOn: Ann Rheum Dis. 2019 Feb;78(2):192-200. - PMID 30396903

3

Response to : 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci

enthalten in: Annals of the rheumatic diseases | 2020

von Glintborg, B. | Loft, A. | Omerovic, E. | +21

CommentOn: Ann Rheum Dis. 2019 Feb;78(2):192-200. - PMID 30396903

4

To switch or not to switch : results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

enthalten in: Annals of the rheumatic diseases | 2019

von Glintborg, B. | Loft, A. | Omerovic, E. | +21

CommentIn: Ann Rheum Dis. 2020 Feb;79(2):e13. - PMID 30487149

5

Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis : a cohort study of patients registered in the Danish biologics registry

enthalten in: Rheumatology (Oxford, England) | 2015

von Jørgensen, T. | Kristensen, L. | Christensen, R. | +27

6

Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry

enthalten in: The Journal of rheumatology | 2014

von Ørnbjerg, L. | Østergaard, M. | Bøyesen, P. | +17

CommentIn: J Rheumatol. 2014 Dec;41(12):2337-9. - PMID 25452176

7

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy : results from the Danish nationwide DANBIO registry

enthalten in: Annals of the rheumatic diseases | 2013

von Glintborg, B. | Østergaard, M. | Krogh, N. | +13

8

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab : results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

enthalten in: Arthritis and rheumatism | 2010

von Hetland, M. | Christensen, I. | Tarp, U. | +13

CommentIn: Arthritis Rheum. 2010 Sep;62(9):2826; author reply 2826-8. - PMID 20556822

9

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

enthalten in: Annals of the rheumatic diseases | 2007

von Hjardem, E. | Østergaard, M. | Pødenphant, J. | +12

1
[1]